BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 27739311)

  • 21. Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma.
    Jin A; Xu Y; Liu S; Jin T; Li Z; Jin H; Lin L; Lin Z
    Exp Mol Pathol; 2014 Feb; 96(1):54-60. PubMed ID: 24263054
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preoperative High Maximum Standardized Uptake Value in Association with Glucose Transporter 1 Predicts Poor Prognosis in Pancreatic Cancer.
    Chikamoto A; Inoue R; Komohara Y; Sakamaki K; Hashimoto D; Shiraishi S; Takamori H; Yamashita YI; Yoshida N; Yamanaka T; Yamashita Y; Baba H
    Ann Surg Oncol; 2017 Jul; 24(7):2040-2046. PubMed ID: 28180987
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of the lymph node ratio in pancreatic ductal adenocarcinoma. Impact on patient stratification and prognosis.
    La Torre M; Cavallini M; Ramacciato G; Cosenza G; Rossi Del Monte S; Nigri G; Ferri M; Mercantini P; Ziparo V
    J Surg Oncol; 2011 Nov; 104(6):629-33. PubMed ID: 21713779
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Re-evaluation of classical prognostic factors in resectable ductal adenocarcinoma of the pancreas.
    Åkerberg D; Ansari D; Andersson R
    World J Gastroenterol; 2016 Jul; 22(28):6424-33. PubMed ID: 27605878
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Toll-like receptor 2 and Toll-like receptor 4 predict favorable prognosis in local pancreatic cancer.
    Lanki MA; Seppänen HE; Mustonen HK; Böckelman C; Juuti AT; Hagström JK; Haglund CH
    Tumour Biol; 2018 Sep; 40(9):1010428318801188. PubMed ID: 30246618
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer.
    Kondo N; Murakami Y; Uemura K; Hayashidani Y; Sudo T; Hashimoto Y; Nakashima A; Sakabe R; Shigemoto N; Kato Y; Ohge H; Sueda T
    Ann Surg Oncol; 2010 Sep; 17(9):2321-9. PubMed ID: 20336387
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biomarkers in pancreatic ductal adenocarcinoma.
    Gallego J; López C; Pazo-Cid R; López-Ríos F; Carrato A
    Clin Transl Oncol; 2017 Dec; 19(12):1430-1437. PubMed ID: 28616721
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer.
    Elebro J; Ben Dror L; Heby M; Nodin B; Jirström K; Eberhard J
    Acta Oncol; 2016; 55(3):286-96. PubMed ID: 26362587
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
    Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
    Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets?
    Brunetti O; Russo A; Scarpa A; Santini D; Reni M; Bittoni A; Azzariti A; Aprile G; Delcuratolo S; Signorile M; Gnoni A; Palermo L; Lorusso V; Cascinu S; Silvestris N
    Oncotarget; 2015 Sep; 6(27):23323-41. PubMed ID: 26259238
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biomarkers for subtypes of pancreatic ductal adenocarcinoma.
    Venkatesan P
    Lancet Oncol; 2017 Dec; 18(12):e718. PubMed ID: 29129444
    [No Abstract]   [Full Text] [Related]  

  • 32. Invasive intraductal papillary-mucinous neoplasm of the pancreas: comparison with pancreatic ductal adenocarcinoma.
    Murakami Y; Uemura K; Sudo T; Hayashidani Y; Hashimoto Y; Nakashima A; Sueda T
    J Surg Oncol; 2009 Jul; 100(1):13-8. PubMed ID: 19384908
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Solid Pseudopapillary Tumor of the Pancreas - Rare Neoplastic Disease in 20-Year-Old Woman.
    Jakub F; Tomáš S; Josef V; Vladislav T; Radek T; Ondřej H
    Klin Onkol; 2018; 31(5):376-379. PubMed ID: 30541325
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathomorphological and histological prognostic factors in curatively resected ductal adenocarcinoma of the pancreas.
    Meyer W; Jurowich C; Reichel M; Steinhäuser B; Wünsch PH; Gebhardt C
    Surg Today; 2000; 30(7):582-7. PubMed ID: 10930222
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metastatic lymph node ratio as an important prognostic factor in pancreatic ductal adenocarcinoma.
    Robinson SM; Rahman A; Haugk B; French JJ; Manas DM; Jaques BC; Charnley RM; White SA
    Eur J Surg Oncol; 2012 Apr; 38(4):333-9. PubMed ID: 22317758
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognosis of malignant intraductal papillary mucinous tumours of the pancreas after surgical resection. Comparison with pancreatic ductal adenocarcinoma.
    Maire F; Hammel P; Terris B; Paye F; Scoazec JY; Cellier C; Barthet M; O'Toole D; Rufat P; Partensky C; Cuillerier E; Lévy P; Belghiti J; Ruszniewski P
    Gut; 2002 Nov; 51(5):717-22. PubMed ID: 12377813
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PD-L1 expression in pancreatic ductal adenocarcinoma is a poor prognostic factor in patients with high CD8
    Yamaki S; Yanagimoto H; Tsuta K; Ryota H; Kon M
    Int J Clin Oncol; 2017 Aug; 22(4):726-733. PubMed ID: 28314962
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer.
    Winter JM; Yeo CJ; Brody JR
    J Surg Oncol; 2013 Jan; 107(1):15-22. PubMed ID: 22729569
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Different clinical presentations of metachronous pulmonary metastases after resection of pancreatic ductal adenocarcinoma: Retrospective study and review of the literature.
    Lovecek M; Skalicky P; Chudacek J; Szkorupa M; Svebisova H; Lemstrova R; Ehrmann J; Melichar B; Yogeswara T; Klos D; Vrba R; Havlik R; Mohelnikova-Duchonova B
    World J Gastroenterol; 2017 Sep; 23(35):6420-6428. PubMed ID: 29085191
    [TBL] [Abstract][Full Text] [Related]  

  • 40. L1 Cell adhesion molecule (L1CAM) expression at the cancer invasive front is a novel prognostic marker of pancreatic ductal adenocarcinoma.
    Tsutsumi S; Morohashi S; Kudo Y; Akasaka H; Ogasawara H; Ono M; Takasugi K; Ishido K; Hakamada K; Kijima H
    J Surg Oncol; 2011 Jun; 103(7):669-73. PubMed ID: 21360711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.